CDXS - NASDAQ
Codexis, Inc.
$2.72
+1.1%Codexis, Inc. discovers, develops, and sells enzymes and other proteins. It offers biocatalyst products and services; intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver protein engineering technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used to discover novel biotherapeutic drug candidates for targeted human diseases, as well as for molecular biology and in vitro diagnostic enzymes. It sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotCodexis, Inc. Management Team
Ms. Georgia L. Erbez
Chief Financial Officer
Compensation
$514,844
Mr. Kevin Norrett M.B.A., M.S.
Chief Operating Officer
Compensation
$726,567
Dr. Alison Moore Ph.D.
Chief Technology Officer & Executive Vice President
Compensation
$586,190
Ms. Carrie McKim
Director of Investor Relations
Dr. Stephen George Dilly MBBS, Ph.D.
President, Chief Executive Officer & Chairman
Compensation
$1,302,513
Ms. Karen Frechou-Armijo
Senior Vice President & Head of Human Resources
Mr. John Schiffhauer
Senior Vice President of Intellectual Property
Dr. Stefan Lutz Ph.D.
Senior Vice President of Research
Codexis, Inc. Insider Positioning
During the last 12 months, insiders have purchased $3.82M and sold $2.75M worth of CDXS shares, resulting in $1.08M of net buying activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
20.7K
27.85K
-28K
-$28K
6-9 Months
1.3M
2.49M
1.6M
2.72M
-232K
-$232K
9-12 Months
545.0K
1.34M
0
0.00
+1.3M
+$1.34M
Top Buyers
Opaleye Management Inc.
10 Percent Owner
$3.82M
Top Sellers
Opaleye Management Inc.
10 Percent Owner
$2.67M
Moore Alison
Director, Officer: President And Ceo
$21K
Erbez Georgia
Officer: See Remarks
$21K
Lutz Stefan
Officer: Chief Scientific Officer
$18K
Wolf Dennis P
Director
$14K
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $1.08M net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
CDXS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 17, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 24, 2025 | June 10, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 25, 2024 | June 11, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 27, 2023 | April 27, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 14, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 29, 2021 | June 15, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 28, 2020 | June 16, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 26, 2019 | June 11, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 27, 2018 | June 11, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | April 28, 2017 | June 14, 2017 | 2017 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.